Article Information
History
- February 8, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jane E Sinclair1,
- Helen J Mayfield2,
- Kirsty R Short1,
- Samuel J Brown1,
- Rajesh Puranik3,4,
- Kerrie Mengersen5,
- John CB Litt6,7,a and
- Colleen L Lau2,a,*
- 1School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia
- 2School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
- 3Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
- 4Sydney Medical School Faculty of Medicine and Health, The University of Sydney, NSW, Australia
- 5School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, Queensland, Australia
- 6Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
- 7Scientific Advisory Committee, Immunisation Coalition, Melbourne, Victoria, Australia
- ↵*Corresponding author
Prof Colleen Lau, School of Public Health, Faculty of Medicine, The University of Queensland, 288 Herston Rd, Herston, Brisbane, Queensland 4006, Australia, Email: colleen.lau{at}uq.edu.au
↵a Contributed equally
Posted February 08, 2022.
Quantifying the risks versus benefits of the Pfizer COVID-19 vaccine in Australia: a Bayesian network analysis
